During the COVID-19 pandemic, the AMMS partnered with CanSino Biologics to develop a COVID-19 vaccine. The development team, led by Chen Wei, registered an experimental COVID-19 vaccine for Phase 1trial on 17 March 2020 to test its safety. The vaccine was tried on 108 healthy volunteers in Wuhan. In April 2020, the vaccine entered Phase 2 to test its effectiveness on 500 volunteers. The vaccine was the first one approved outside of clinical trials in an expedite decision, which authorized its use only by the Chinese military.